论文部分内容阅读
目的使用BRAF VE1抗体免疫组化法检测结直肠癌样本中BRAF V600E位点突变,并分析其敏感性和特异性。方法采用ARMS法和免疫组化法检测36例结直肠癌组织中BRAF V600E突变状态,并使用测序验证。结果免疫组化法检测结直肠癌样本中BRAF VE1抗体的敏感性为100%,特异性为62.9%。与甲状腺样本BRAF V600E突变相比,结直肠癌标本为细胞质着色,染色呈棕黄色。结论免疫组化法可高效、快速、低成本初步筛选结直肠癌的BRAF V600E突变,但需分子检测进一步确认。
Objective To detect the mutation of BR600 V600E locus in colorectal cancer samples by immunohistochemistry with BRAF VE1 antibody and analyze its sensitivity and specificity. Methods The mutation status of BRAF V600E in 36 cases of colorectal cancer tissues was detected by ARMS and immunohistochemistry, and was verified by sequencing. Results The sensitivity and specificity of BRAF VE1 antibody in detecting colorectal cancer samples by immunohistochemistry were 100% and 62.9% respectively. Colorectal cancer specimens were stained cytoplasm and stained brownish yellow compared to the thyroid sample BRAF V600E mutation. Conclusions Immunohistochemistry can be used to screen BRAF V600E mutation of colorectal cancer efficiently, rapidly and at low cost, but it needs further confirmation by molecular detection.